These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19397467)

  • 21. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
    Roy P; Bonello L; Torguson R; de Labriolle A; Lemesle G; Slottow TL; Steinberg DH; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Dec; 102(12):1614-7. PubMed ID: 19064014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
    Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ
    Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cholestasic toxic hepatitis due to clopidogrel in a patient with multiple conditions].
    Etxeberria-Lekuona D; Méndez-López I; Mercado MR; Oteiza J; Arteaga M; Jarne V
    An Sist Sanit Navar; 2016 Apr; 39(1):143-8. PubMed ID: 27125614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Faxon DP; Lawler E; Young M; Gaziano M; Kinlay S
    Circ Cardiovasc Interv; 2012 Jun; 5(3):372-80. PubMed ID: 22668555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury.
    Willens HJ
    Am J Ther; 2000 Sep; 7(5):317-8. PubMed ID: 11317178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of prasugrel in a patient with clopidogrel hypersensitivity.
    Peppard SR; Held-Godgluck BM; Beddingfield R
    Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
    Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epistaxis as the reason for premature discontinuation of clopidogrel after percutaneous coronary angioplasty with stent implantation.
    Jura-Szołtys E; Chudek J
    Kardiol Pol; 2011; 69(8):817-23. PubMed ID: 21850627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues.
    Khambekar SK; Kovac J; Gershlick AH
    Heart; 2004 Mar; 90(3):e14. PubMed ID: 14966075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.